Kenneth A Katz

Summary

Publications

  1. doi request reprint Time to nip "seeding trials" in the bud
    Kenneth A Katz
    Epidemic Intelligence Service, Centers for Disease Control and Prevention
    Arch Dermatol 144:403-4. 2008
  2. ncbi request reprint Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients
    Kenneth A Katz
    Harvard Medical School, Boston, Massachusetts 02115, USA
    J Invest Dermatol 118:1038-43. 2002
  3. ncbi request reprint Statistical reviewing policies in dermatology journals: results of a questionnaire survey of editors
    Kenneth A Katz
    Department of Dermatology, University of Pennsylvania, Philadelphia 19104, USA
    J Am Acad Dermatol 51:234-40. 2004
  4. ncbi request reprint Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: an unconvincing proposal
    Kenneth A Katz
    J Am Acad Dermatol 53:547-51. 2005
  5. ncbi request reprint AMEVIVE's advertisements: problematic?
    Kenneth A Katz
    Arch Dermatol 141:1602-4; discussion 1604. 2005
  6. ncbi request reprint Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study
    Kenneth A Katz
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Am Acad Dermatol 55:814-22. 2006
  7. doi request reprint Topical tretinoin, lung cancer, and lung-related mortality
    Kenneth A Katz
    Arch Dermatol 144:945-6. 2008

Collaborators

Detail Information

Publications7

  1. doi request reprint Time to nip "seeding trials" in the bud
    Kenneth A Katz
    Epidemic Intelligence Service, Centers for Disease Control and Prevention
    Arch Dermatol 144:403-4. 2008
  2. ncbi request reprint Incidence and risk factors associated with a second squamous cell carcinoma or basal cell carcinoma in psoralen + ultraviolet a light-treated psoriasis patients
    Kenneth A Katz
    Harvard Medical School, Boston, Massachusetts 02115, USA
    J Invest Dermatol 118:1038-43. 2002
    ..Patients who develop a squamous cell carcinoma after starting psoralen + ultraviolet A therapy should be closely monitored for a subsequent squamous cell carcinoma...
  3. ncbi request reprint Statistical reviewing policies in dermatology journals: results of a questionnaire survey of editors
    Kenneth A Katz
    Department of Dermatology, University of Pennsylvania, Philadelphia 19104, USA
    J Am Acad Dermatol 51:234-40. 2004
    ..Problems with statistical methods and reporting have been noted in articles published in dermatology journals. Conclusions presented in published reports may be misleading if based on inappropriate or misinterpreted statistical analysis...
  4. ncbi request reprint Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: an unconvincing proposal
    Kenneth A Katz
    J Am Acad Dermatol 53:547-51. 2005
  5. ncbi request reprint AMEVIVE's advertisements: problematic?
    Kenneth A Katz
    Arch Dermatol 141:1602-4; discussion 1604. 2005
  6. ncbi request reprint Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study
    Kenneth A Katz
    Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Am Acad Dermatol 55:814-22. 2006
    ..The ethics and science of using placebo control groups in clinical trials have been widely debated. Few studies, however, have examined factors associated with choice of control group...
  7. doi request reprint Topical tretinoin, lung cancer, and lung-related mortality
    Kenneth A Katz
    Arch Dermatol 144:945-6. 2008